Distribution of Nicotinamide Mononucleotide after Intravenous Injection in Normal and Ischemic Stroke Mice.

Zheng SL, Wang DS, Dong X, Guan YF, Qi Q, Hu WJ, Hong C, Zhang C, Miao CY

Current pharmaceutical biotechnology1 Jan 2023Cited by 6 (Europe PMC)

PMID35593333DOI10.2174/1389201023666220518113219PepBankPUB-35593333

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

9 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Pharmacokinetics
In normal and MCAO mice, intravenous NMN sharply increased serum NMN, which then rapidly declined within 15 min.
In plain wordsIn normal and stroke-model mice, injected NMN sharply increased blood NMN, which then rapidly decreased.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
MixedSerum NMN time course
Study
mousen: not reported in source
Normal and MCAO mice
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
300 mg/kg · intravenousAs given in this study (mouse).
Source sentences
Summary
Under either normal or MCAO conditions, serum NMN levels sharply increased after intravenous NMN administration and then decreased rapidly within 15 min, while serum NAD levels remained unchanged during 30 min observation.
1 context sentence(design, population, supporting numbers)
Summary · context
NMN and NAD levels were determined using ultra-high-performance liquid chromatography tandem mass spectrometry in biological samples from mice with or without middle cerebral artery occlusion (MCAO) at different time points post intravenous NMN injection (300 mg/kg).
Report a problemFND-3559333301
02AnimalAnimal study (in vivo)Pharmacokinetics
In normal and MCAO mice, serum NAD remained unchanged during 30 min after intravenous NMN.
In plain wordsIn normal and stroke-model mice, injected NMN did not change blood NAD during observation.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
No significant changeSerum NAD levels
Study
mousen: not reported in source
Normal and MCAO mice
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
300 mg/kg · intravenous · 30 min observationAs given in this study (mouse).
Source sentences
Summary
Under either normal or MCAO conditions, serum NMN levels sharply increased after intravenous NMN administration and then decreased rapidly within 15 min, while serum NAD levels remained unchanged during 30 min observation.
1 context sentence(design, population, supporting numbers)
Summary · context
NMN and NAD levels were determined using ultra-high-performance liquid chromatography tandem mass spectrometry in biological samples from mice with or without middle cerebral artery occlusion (MCAO) at different time points post intravenous NMN injection (300 mg/kg).
Report a problemFND-3559333302
03AnimalAnimal study (in vivo)Pharmacokinetics
In normal and MCAO mice, NMN accumulated in tissues over time, with the highest concentrations in kidney.
In plain wordsIn normal and stroke-model mice, NMN accumulated in tissues over time and reached its highest levels in kidney.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreaseNMN tissue accumulation
Study
mousen: not reported in source
Normal and MCAO mice
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
300 mg/kg · intravenousAs given in this study (mouse).
Source sentences
Summary
Both substances displayed tissue accumulation over time and stored faster under MCAO conditions, with kidney having the highest concentrations.
1 context sentence(design, population, supporting numbers)
Summary · context
NMN and NAD levels were determined using ultra-high-performance liquid chromatography tandem mass spectrometry in biological samples from mice with or without middle cerebral artery occlusion (MCAO) at different time points post intravenous NMN injection (300 mg/kg).
Report a problemFND-3559333303
04AnimalAnimal study (in vivo)Pharmacokinetics
In normal and MCAO mice, NAD accumulated in tissues over time, with the highest concentrations in kidney.
In plain wordsIn normal and stroke-model mice, NAD accumulated in tissues over time and reached its highest levels in kidney.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreaseNAD tissue accumulation
Study
mousen: not reported in source
Normal and MCAO mice
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
300 mg/kg · intravenousAs given in this study (mouse).
Source sentences
Summary
Both substances displayed tissue accumulation over time and stored faster under MCAO conditions, with kidney having the highest concentrations.
1 context sentence(design, population, supporting numbers)
Summary · context
NMN and NAD levels were determined using ultra-high-performance liquid chromatography tandem mass spectrometry in biological samples from mice with or without middle cerebral artery occlusion (MCAO) at different time points post intravenous NMN injection (300 mg/kg).
Report a problemFND-3559333304
05AnimalAnimal study (in vivo)Pharmacokinetics
After intravenous NMN in mice, NMN accumulated faster in tissues under MCAO than normal conditions.
In plain wordsIn mice given NMN, tissue NMN accumulated faster under stroke-model conditions than normal conditions.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreaseNMN tissue accumulation rate under MCAO
Study
mousen: not reported in source
Normal and MCAO mice
Comparator
Normal conditions
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
300 mg/kg · intravenousAs given in this study (mouse).
Source sentences
Summary
Both substances displayed tissue accumulation over time and stored faster under MCAO conditions, with kidney having the highest concentrations.
1 context sentence(design, population, supporting numbers)
Summary · context
NMN and NAD levels were determined using ultra-high-performance liquid chromatography tandem mass spectrometry in biological samples from mice with or without middle cerebral artery occlusion (MCAO) at different time points post intravenous NMN injection (300 mg/kg).
Report a problemFND-3559333305
06AnimalAnimal study (in vivo)Pharmacokinetics
After intravenous NMN in mice, NAD accumulated faster in tissues under MCAO than normal conditions.
In plain wordsIn mice given NMN, tissue NAD accumulated faster under stroke-model conditions than normal conditions.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreaseNAD tissue accumulation rate under MCAO
Study
mousen: not reported in source
Normal and MCAO mice
Comparator
Normal conditions
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
300 mg/kg · intravenousAs given in this study (mouse).
Source sentences
Summary
Both substances displayed tissue accumulation over time and stored faster under MCAO conditions, with kidney having the highest concentrations.
1 context sentence(design, population, supporting numbers)
Summary · context
NMN and NAD levels were determined using ultra-high-performance liquid chromatography tandem mass spectrometry in biological samples from mice with or without middle cerebral artery occlusion (MCAO) at different time points post intravenous NMN injection (300 mg/kg).
Report a problemFND-3559333306
07AnimalAnimal study (in vivo)Pharmacokinetics
After intravenous NMN in mice, NMN accumulated in brain earlier than NAD.
In plain wordsIn mice given NMN, brain NMN accumulated earlier than NAD.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
Not applicableBrain accumulation timing
Study
mousen: not reported in source
Normal and MCAO mice
Comparator
NAD accumulation
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
300 mg/kg · intravenousAs given in this study (mouse).
Source sentences
Summary
Particularly, NMN accumulated earlier than NAD in the brain.
1 context sentence(design, population, supporting numbers)
Summary · context
NMN and NAD levels were determined using ultra-high-performance liquid chromatography tandem mass spectrometry in biological samples from mice with or without middle cerebral artery occlusion (MCAO) at different time points post intravenous NMN injection (300 mg/kg).
Report a problemFND-3559333307
08AnimalAnimal study (in vivo)Efficacy outcome
In MCAO mice, NMN reduced cerebral infarction at 24 h after MCAO.
In plain wordsIn stroke-model mice, NMN reduced brain infarction.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseCerebral infarction
Study
mousen: not reported in source
MCAO ischemic stroke mice
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
300 mg/kg · intravenousAs given in this study (mouse).
Source sentences
Summary
Moreover, NMN reduced cerebral infarction at 24 h post-MCAO.
1 context sentence(design, population, supporting numbers)
Summary · context
NMN and NAD levels were determined using ultra-high-performance liquid chromatography tandem mass spectrometry in biological samples from mice with or without middle cerebral artery occlusion (MCAO) at different time points post intravenous NMN injection (300 mg/kg).
Report a problemFND-3559333308
09AnimalAnimal study (in vivo)Safety outcome
In mice given intravenous NMN for acute toxicity testing, no acute toxicity was observed for 14 days.
In plain wordsIn mice given intravenous NMN, researchers observed no acute toxicity for 14 days.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
No significant changeAcute toxicity
Study
mousen: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
2 g/kg · intravenous · 14 daysAs given in this study (mouse).
Source sentences
Summary
No acute toxicity was observed for 14 days.
2 context sentences(design, population, supporting numbers)
Summary · context
2 g/kg NMN was used in the acute toxicity test.
Summary · context
NMN and NAD levels were determined using ultra-high-performance liquid chromatography tandem mass spectrometry in biological samples from mice with or without middle cerebral artery occlusion (MCAO) at different time points post intravenous NMN injection (300 mg/kg).
Report a problemFND-3559333309

Studies that did not test the peptide alone2

In this study, NMN (nicotinamide mononucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking NMN (nicotinamide mononucleotide).

10AnimalNot a test of NMN (nicotinamide mononucleotide) aloneAnimal study (in vivo)Mechanism
In mice, NRK1 involved in NMN uptake had its highest expression in kidney among the tissues examined.
In plain wordsIn mice, the NMN uptake factor NRK1 had higher expression in kidney than other examined tissues.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
Not applicableNRK1 tissue expression
Study
mousen: not reported in source
Normal and MCAO mice
Comparator
Other tissues
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
NRK1 and SLC12A8 involved in two pathways of NMN uptake exhibited the highest expressions in kidney and colon, respectively, among 11 different tissues.
1 context sentence(design, population, supporting numbers)
Summary · context
NMN and NAD levels were determined using ultra-high-performance liquid chromatography tandem mass spectrometry in biological samples from mice with or without middle cerebral artery occlusion (MCAO) at different time points post intravenous NMN injection (300 mg/kg).
In this study, NMN (nicotinamide mononucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NMN (nicotinamide mononucleotide).
Report a problemFND-3559333310
11AnimalNot a test of NMN (nicotinamide mononucleotide) aloneAnimal study (in vivo)Mechanism
In mice, SLC12A8 involved in NMN uptake had its highest expression in colon among the tissues examined.
In plain wordsIn mice, the NMN uptake factor SLC12A8 had higher expression in colon than other examined tissues.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
Not applicableSLC12A8 tissue expression
Study
mousen: not reported in source
Normal and MCAO mice
Comparator
Other tissues
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
NRK1 and SLC12A8 involved in two pathways of NMN uptake exhibited the highest expressions in kidney and colon, respectively, among 11 different tissues.
1 context sentence(design, population, supporting numbers)
Summary · context
NMN and NAD levels were determined using ultra-high-performance liquid chromatography tandem mass spectrometry in biological samples from mice with or without middle cerebral artery occlusion (MCAO) at different time points post intravenous NMN injection (300 mg/kg).
In this study, NMN (nicotinamide mononucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NMN (nicotinamide mononucleotide).
Report a problemFND-3559333311

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.